Browse & search snapshots

Notification for WTO member countries under Canada's Access to Medicines Regime Countries that are members of the World Trade Organization (WTO), as listed on Schedule 3 to Canada's Patent Act , are required to notify the WTO of their plans to use Canada's Access to Medicines…

Notification diagram for WTO member countries under Canada's Access to Medicines Regime The following diagram illustrates the information that should be provided by a Schedule 3 country to the World Trade Organization. More complete details are available in Notification…

Notification for least-developed countries under Canada's Access to Medicines Regime Least-developed countries, as identified on Schedule 2 to Canada's Patent Act , planning to use Canada's Access to Medicines Regime are required to notify the World Trade Organization (WTO), if…

Notification diagram for least-developed countries under Canada's Access to Medicines Regime The following diagram illustrates what information should be provided to which authority in the notification process. More complete details are available in Notification Requirements for…

Importing countries finding a drug company under Canada's Access to Medicines Regime Countries that want to use Canada's Access to Medicines Regime are required to make an arrangement with a Canadian pharmaceutical company that is prepared to manufacture the needed drug or…

Adding drugs and medical devices to the list of eligible products under Canada's Access to Medicines Regime If a particular drug or medical device is needed by a country but is not on Schedule 1 , the list of eligible products included in Canada's Patent Act , the importing…

Good faith clause under Canada's Access to Medicines Regime The legislation establishing Canada's Access to Medicines Regime contains a "Good Faith Clause" that provides patent holders with the right to challenge a compulsory licence in the Federal Court of Canada. A challenge…

Anti-diversionary measures under Canada's Access to Medicines Regime Canada's Access to Medicines Regime includes a number of measures to prevent diversion of drugs and medical devices to unintended markets. Licensed products must have anti-diversionary features, including…

Séances de discussions techniques Modernisation de la réglementation sur les produits thérapeutiques Sommaire de la rétroaction reçue Les séances de discussions techniques de Santé Canada sur la modernisation de la réglementation touchant les produits thérapeutiques (médicaments…

Herbicide Tolerant HT4 Maize – MON 87429 In 2019, Health Canada received a submission to allow the sale of a genetically modified (GM) maize variety referred to as herbicide tolerant HT4 maize – MON 87429. This maize variety has been genetically modified to be tolerant to…